Government Expands Cancer Medicine Price Controls; Cancer Patients Expected to Save ₹2,500 Crore Annually

1. At a Glance

• The Government has approved a cap on trade margins for non-scheduled anti-cancer drugs. The margin is limited to 30% of MRP. Prices are expected to fall by up to 70%, and patients are expected to save ₹2,500 crore a year [1].
• This extends the Trade Margin Rationalisation (TMR) approach. TMR was first tried as a pilot on 42 cancer drugs in 2019 [1][2].
• India has two layers of drug price control. Scheduled drugs (those on the NLEM) get a government-fixed ceiling price. Non-scheduled drugs are covered only by an annual limit on MRP increases, and now, for these cancer drugs, by a margin cap [1][5].
• Why it matters for UPSC: the topic covers health financing and out-of-pocket expenditure (OOPE), pharma regulation (DPCO 2013, NPPA), the state-vs-market pricing debate, and Universal Health Coverage (GS-II and GS-III).

2. Why in the News

• 8 Oct 2026: The Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers) announced that the 30% margin cap will apply to all non-scheduled anti-cancer drugs [1].
• What triggered it: NPPA's analysis of market data found that non-scheduled cancer drugs carry an average mark-up of about 170%, and 700% or more in some cases [1].
• Maharashtra, Rajasthan and Karnataka, along with patients and civil society, had raised concerns about excessive prices [1].

3. Background & Evolution

• The base framework: Drug prices are regulated under the Drugs (Prices Control) Order, 2013 (DPCO 2013) [5].
• How the NLEM fits in: The Ministry of Health & Family Welfare notifies the National List of Essential Medicines (NLEM). The NLEM forms Schedule-I of DPCO 2013, and NPPA fixes ceiling prices for the drugs on it [3][5].
• Rules for non-scheduled drugs: Manufacturers may raise MRP by no more than 10% in any 12 months [3][5].
• Milestones:
• 26 Feb 2019: NPPA used its extraordinary powers in public interest under Para 19 of DPCO 2013. It capped trade margins at up to 30% on 42 non-scheduled anti-cancer drugs as a pilot [2][3].
• Mar 2019: The MRPs of 390 anti-cancer non-scheduled medicines were cut by up to 87% [4].
• Final outcome of the 2019 move: MRPs of 526 brands fell by about 50% on average (up to about 90–91%), saving patients about ₹984 crore a year [1][2].
• NLEM 2022: Re-fixing ceiling prices cut prices by about 17% on average. Reported annual savings are ₹3,788 crore in one release [7] and ₹3,802 crore in another [3].
• 2024: MRPs of Trastuzumab, Osimertinib and Durvalumab were set to fall because of a customs duty exemption and lower GST rates [8].
• Budget 2025-26: 36 life-saving drugs (for cancer, rare diseases and chronic diseases) were fully exempted from Basic Customs Duty (BCD). 6 more get a concessional BCD of 5% [9].
• 8 Oct 2026: The margin cap was extended to all non-scheduled anti-cancer drugs [1].

4. Core Static Facts

Key terms:

• Scheduled formulation: a drug listed in NLEM / DPCO Schedule-I, sold under a ceiling price.
• Non-scheduled formulation: any other drug. Its MRP may rise by at most 10% a year [5].
• Trade margin: the gap between the price at which a drug is bought for sale (by distributor or retailer) and the MRP charged to the consumer [1].

5. Multi-Dimensional Analysis

Economic

• Cutting margins of about 170% down to 30% squeezes distributor, retailer and hospital-pharmacy profits. The manufacturer's price is not directly controlled [1].
• Requiring manufacturers to keep production at current levels guards against companies cutting supply because the business is less profitable [1].
• The cap works alongside fiscal measures: the 2025-26 customs exemptions mean about ₹2,600 crore of indirect tax revenue forgone [9].

Social

• Cancer treatment brings heavy out-of-pocket spending for patients and families, which can push households into poverty [1].
• Prices differ between retail, hospital and online pharmacies. Patients tied to hospital pharmacies are especially exposed [1].

Legal / Regulatory

• Para 19 of DPCO lets the regulator control prices beyond the NLEM "in public interest" [2].
• Margin capping is a lighter tool than ceiling prices. It controls the supply-chain mark-up and leaves the manufacturer's price untouched [1].

Governance / Federal

• The demand came from States (Maharashtra, Rajasthan, Karnataka), which shows cooperative federalism at work in health [1].
• The process involves two bodies: DGHS (under MoHFW) chooses the drugs, and NPPA (under DoP) notifies them. Coordinating the two is a potential bottleneck [1].

Health systems

• The cap complements other measures: Day Care Cancer Centres in all district hospitals within 3 years, with 200 planned for 2025-26 [10].

6. Recent Developments (last 12–18 months)

• Feb 2025: The Budget 2025-26 exempted 36 life-saving drugs from BCD and gave 6 a concessional 5% rate. Drugs supplied under Patient Assistance Programmes were fully exempted [9].
• Feb 2025: The Day Care Cancer Centres plan was announced: 200 centres in 2025-26 [10].
• 25 Mar 2025: Ceiling prices were in force for 928 scheduled formulations [6].
• 1 Dec 2025: Ceiling prices were in force for 935 scheduled formulations [3].
• 8 Oct 2026: The 30% margin cap on all non-scheduled anti-cancer drugs was approved [1].

7. Prelims Hooks

• The new cap limits margins on non-scheduled anti-cancer drugs to 30% of MRP [1].
• Expected saving: ₹2,500 crore a year; prices to fall by up to 70% [1].
• The drug list is finalised by an expert committee under DGHS, not by NPPA [1].
• NPPA issues the final notification and works under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers [1].
• The 2019 pilot used Para 19 of DPCO 2013 [2].
• The 2019 TMR covered 42 non-scheduled anti-cancer drugs and 526 brands, saving about ₹984 crore a year [2].
• NPPA's meeting invoking Para 19 was held on 26 February 2019 [3].
• NLEM is notified by MoHFW and forms Schedule-I of DPCO 2013 [3].
• MRPs of non-scheduled drugs may rise by at most 10% in 12 months [5].
• NPPA found an average mark-up of about 170% on non-scheduled cancer drugs [1].
• Coverage includes patented and imported drugs as well as generics [1].
• Budget 2025-26: 36 drugs fully exempt from BCD; 6 at a concessional 5% [9].
• In 2024, customs exemption and GST cuts were announced for Trastuzumab, Osimertinib and Durvalumab [8].

8. Why the 30% Cap Rests on Weak Legal Ground

• The cap uses an emergency power, not a permanent rule
• TMR (Trade Margin Rationalisation, which limits how much sellers add on top of the company's price) is done under Para 19 of DPCO 2013. Para 19 is an extraordinary power for use "in public interest" [2].
• The Parliamentary Standing Committee on Chemicals and Fertilisers noted that DPCO 2013 allows margin capping only temporarily [11].

• So a policy covering every non-scheduled cancer drug depends on a power meant for exceptional cases. Companies can challenge it in court as stretching that power too far.

• Parliament itself has asked for a permanent law

• The Committee recommended amending DPCO 2013 so that it contains clear legal provisions for TMR [11].
• In 2026 it again flagged the absence of a permanent TMR framework, and asked for one within a fixed deadline [12].
• Until that happens, each extension of the cap is a one-time order that a later government can quietly let lapse.

9. Why a Price Cut on Paper May Not Reach the Patient

• Patients cannot see the margin, so they cannot check it
• The margin is the gap between the PTS (price to stockist, the price at which the company sells to the wholesaler) and the MRP.
• The Standing Committee found that PTS data is not made public [11].

• A patient sees only the MRP. They cannot tell whether the 30% limit is being followed.

• Hospital pharmacies are the weakest point

• The note says patients tied to hospital pharmacies are the most exposed [1].
• The Committee found NPPA's price-monitoring data is incomplete. It asked NPPA to collect data from hospital sales and rural markets too [12].

• If the regulator does not track hospital sales, the cap protects the buyer at the chemist's shop but not the patient on a hospital drip.

• Catching overcharging does not mean recovering the money

• The Committee reported large overcharged amounts not yet recovered because they are stuck in court cases [12].
• It asked for a fast-track dispute system and a dedicated legal cell [12].

• A company that overcharges today and pays years later, if at all, has little reason to follow the rule.

• Online pharmacies sit outside clear rules

• The Committee found online drug platforms have no proper system to ensure fair prices or genuine products. It asked for a regulatory framework [11].
• Cancer patients increasingly buy online. The cap needs a way to reach those sales.

10. Why One Flat 30% Is Not What WHO Advises

• A flat percentage gives the most profit on the costliest drugs
• 30% of a ₹1,000 tablet is ₹300. 30% of a ₹1 lakh injection is ₹30,000, even though both may cost about the same to store and sell.

• So the seller still earns most on exactly the drugs that ruin families.

• WHO recommends a falling (regressive) mark-up

• WHO's 2020 Guideline on Country Pharmaceutical Pricing Policies suggests the mark-up rate should fall as the price rises, not stay the same for all prices [13].
• It also says mark-up rules should go together with other pricing tools, should be open about rebates and discounts, and should be reviewed regularly to protect patients from out-of-pocket spending [13].

• India's cap does the first part (it sits alongside ceiling prices and customs relief [9]). It does not yet do the falling-rate design or the disclosure of discounts.

• The cap does not touch the company's own price

• Margin capping controls only what is added after the company sells. The manufacturer's price stays free [1].
• For patented imported drugs, the company's price is the main cost. Here the cap can only trim the edges.
• The annual 10% limit on MRP increases [5] slows a company from raising its base price to make up for the cut, but it does not stop it.

11. Will Chemists Stop Stocking Cancer Drugs?

• The strongest objection
• Specialty cancer drugs need cold storage, small-volume handling and costly stock that may sit unsold. Traders argue high margins pay for this.

• If the margin falls from about 170% to 30% [1], small-town chemists may simply stop keeping these drugs. Patients would then have to travel to big cities.

• What is right about it

• The rule that guards supply binds only manufacturers, who must keep production at current levels [1]. Nothing in it obliges a wholesaler or chemist to keep stocking a drug.

• The Committee's own concern that NPPA lacks rural sales data [12] means a supply gap in small towns may not be noticed quickly.

• Why the objection does not defeat the policy

• A 30% margin is still a real margin. NPPA found the average mark-up was about 170%, and 700% or more in some cases [1]. That is far above any storage or handling cost.
• The 2019 pilot cut prices for 526 brands [2], and the government has chosen to extend it rather than reverse it [1].

• The Standing Committee, after reviewing the pilot, called TMR "a viable means of controlling drug prices" [11].

• What follows: NPPA should track availability in district and rural markets after the cap, not only prices, so that any stocking gap shows up early.

12. What Parliament Wants NPPA to Do Next

• Bring non-scheduled drugs under proper price control
• Today NPPA fixes ceiling prices only for scheduled (NLEM) drugs. Non-scheduled drugs face only the 10% yearly limit [5].

• The Committee recommended extending NPPA control to non-scheduled formulations and fixed-dose combinations (FDCs, tablets that combine two or more drugs) [11].

• Look again at cost-based pricing

• The Committee asked the government to study whether pricing based on the cost of making a drug could return, through a change in law [12].

• DPCO 2013 fixes ceiling prices from market averages, not from production cost. This would be a major shift.

• Close the scheduled vs non-scheduled loophole

• The Committee asked for a review of how medicines are classed, to close pricing gaps [12].

• The mechanism: a company can change a drug's strength or combination so that it falls outside NLEM and escapes the ceiling price.

• Let the public take part

• The Committee found little public involvement in price-setting. It asked for more awareness and participation [12].
• States like Maharashtra, Rajasthan and Karnataka pushed for this cap [1]. That shows outside pressure can move NPPA, but there is no regular channel for it.

13. Anchors for Answers

• Data: NPPA found an average trade mark-up of about 170% (700%+ in some cases) on non-scheduled cancer drugs [1]
• Data: The 2019 TMR pilot cut MRPs of 526 brands and saved patients about ₹984 crore a year [2]
• Report/Committee: Standing Committee on Chemicals and Fertilisers (Chair: Azad Kirti Jha), report on price rise of medicines, summarised Dec 2025: TMR is viable, but DPCO allows it only temporarily; amend DPCO [11]
• Report/Committee: Same Committee's 2026 review of NPPA: no permanent TMR framework, overcharged amounts stuck in litigation, asks for a fast-track legal cell [12]
• Law/Case: Para 19 of DPCO 2013 (extraordinary powers in public interest) used for the margin cap [2]
• Comparison: WHO Guideline on Country Pharmaceutical Pricing Policies (2020) advises a regressive mark-up (lower rate on costlier drugs) plus disclosure of rebates; India uses a flat 30% [13]
• Scheme: Day Care Cancer Centres in all district hospitals within 3 years (200 in 2025-26): cuts travel and treatment costs alongside the price cap [10]

14. Mains Relevance

• GS-II: Issues relating to the development and management of the Social Sector/Services relating to Health; Government policies and interventions.
• GS-III: Indian economy (pricing policy, market regulation); Government budgeting (customs and GST relief on drugs).
• GS-IV (case-study angle): Profiteering on life-saving drugs; corporate ethics.
• Possible questions: 1. "Trade Margin Rationalisation is a more market-friendly alternative to ceiling prices for controlling drug costs." Critically examine this with reference to anti-cancer medicines in India. 2. High out-of-pocket expenditure remains the main barrier to Universal Health Coverage for diseases like cancer. Evaluate recent regulatory and fiscal measures to address it. 3. Discuss the role of NPPA and the DPCO 2013 in balancing affordability against the availability of essential medicines.

15. Related Topics to Study Next

• NLEM 2022 and how it is revised: it is the base for scheduled price control [3].
• DPCO 2013: its ceiling-price method and Para 19 powers [5].
• Day Care Cancer Centres and Budget 2025-26 health measures: they complement the price cap [10].
• Customs and GST relief on medicines: the fiscal route to affordability [8][9].
• Ayushman Bharat PM-JAY and Jan Aushadhi: the insurance and generics routes to cutting OOPE.
• Patents Act and TRIPS flexibilities (compulsory licensing): why the cap's coverage of patented drugs matters.
• NPCDCS / NP-NCD: screening programmes for cancer and other non-communicable diseases.

16. NCERT Concepts to Revise

• Price ceiling (Economy): Scheduled drugs get a government-fixed ceiling price; the note contrasts this with the lighter margin cap.
• Maximum Retail Price (Economy): The 30% cap is measured against MRP, and non-scheduled drugs can raise MRP only 10% a year.
• Price control (Economy): The whole policy is state price regulation under DPCO 2013, with the state-versus-market debate behind it.
• Supply chain (Economy): Trade margins are the mark-ups added by distributors and retailers between manufacturer and patient.
• Compulsory licensing (Economy): Helps explain how patented drugs are made affordable, which matters because the cap covers patented drugs.
• Standing committee (Polity): The Standing Committee on Chemicals and Fertilisers reviewed TMR and urged a permanent legal framework.

17. Common Errors / Trap Areas

• Wrong ministry: NPPA sits under the Ministry of Chemicals & Fertilizers (DoP), not MoHFW. MoHFW handles the NLEM and DGHS [1][3].
• Ceiling price is not the same as a margin cap: Scheduled drugs get ceiling prices. The 2026 move caps margins on non-scheduled drugs [1].
• Mixing up 2019 and 2026 numbers: 2019 meant 42 drugs, 526 brands and ₹984 crore. 2026 means all non-scheduled cancer drugs and ₹2,500 crore [1][2].
• Inconsistent 2019 figures across PIB releases: an interim March 2019 release says 87% (390 medicines) [4]. A 2021 release says up to 90% [2]. The 2026 release says up to 91% [1]. In an exam, answer "up to ~90%" or "average ~50%".
• Who selects the drugs: an expert committee under DGHS, not NPPA itself [1].
• Not verified from whitelisted sources: that DPCO is issued under Section 3 of the Essential Commodities Act, 1955, and that NPPA was set up in 1997. Check both before relying on them.